JP6889101B2 - グルタミナーゼ阻害剤の結晶形態 - Google Patents

グルタミナーゼ阻害剤の結晶形態 Download PDF

Info

Publication number
JP6889101B2
JP6889101B2 JP2017506401A JP2017506401A JP6889101B2 JP 6889101 B2 JP6889101 B2 JP 6889101B2 JP 2017506401 A JP2017506401 A JP 2017506401A JP 2017506401 A JP2017506401 A JP 2017506401A JP 6889101 B2 JP6889101 B2 JP 6889101B2
Authority
JP
Japan
Prior art keywords
cancer
compound
tumor
crystal
lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017506401A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017523991A5 (enExample
JP2017523991A (ja
Inventor
ティモシー エフ． スタントン，
ティモシー エフ． スタントン，
ジェイムズ ジェイ． スプリンガー，
ジェイムズ ジェイ． スプリンガー，
ジャクリーン エヌ． ウィリアムズ，
ジャクリーン エヌ． ウィリアムズ，
Original Assignee
キャリセラ バイオサイエンシーズ， インコーポレイテッド
キャリセラ バイオサイエンシーズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キャリセラ バイオサイエンシーズ， インコーポレイテッド, キャリセラ バイオサイエンシーズ， インコーポレイテッド filed Critical キャリセラ バイオサイエンシーズ， インコーポレイテッド
Publication of JP2017523991A publication Critical patent/JP2017523991A/ja
Publication of JP2017523991A5 publication Critical patent/JP2017523991A5/ja
Application granted granted Critical
Publication of JP6889101B2 publication Critical patent/JP6889101B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2017506401A 2014-08-07 2015-08-07 グルタミナーゼ阻害剤の結晶形態 Expired - Fee Related JP6889101B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462034547P 2014-08-07 2014-08-07
US62/034,547 2014-08-07
PCT/US2015/044301 WO2016022969A1 (en) 2014-08-07 2015-08-07 Crystal forms of glutaminase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019208032A Division JP2020037588A (ja) 2014-08-07 2019-11-18 グルタミナーゼ阻害剤の結晶形態

Publications (3)

Publication Number Publication Date
JP2017523991A JP2017523991A (ja) 2017-08-24
JP2017523991A5 JP2017523991A5 (enExample) 2018-08-30
JP6889101B2 true JP6889101B2 (ja) 2021-06-18

Family

ID=55264662

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017506401A Expired - Fee Related JP6889101B2 (ja) 2014-08-07 2015-08-07 グルタミナーゼ阻害剤の結晶形態
JP2019208032A Pending JP2020037588A (ja) 2014-08-07 2019-11-18 グルタミナーゼ阻害剤の結晶形態
JP2021108805A Withdrawn JP2021165286A (ja) 2014-08-07 2021-06-30 グルタミナーゼ阻害剤の結晶形態

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019208032A Pending JP2020037588A (ja) 2014-08-07 2019-11-18 グルタミナーゼ阻害剤の結晶形態
JP2021108805A Withdrawn JP2021165286A (ja) 2014-08-07 2021-06-30 グルタミナーゼ阻害剤の結晶形態

Country Status (13)

Country Link
US (2) US10316030B2 (enExample)
EP (1) EP3193876B1 (enExample)
JP (3) JP6889101B2 (enExample)
KR (1) KR20170082494A (enExample)
CN (1) CN106999490A (enExample)
AU (2) AU2015300825B2 (enExample)
BR (1) BR112017002403A2 (enExample)
CA (1) CA2957225A1 (enExample)
EA (1) EA037738B1 (enExample)
IL (1) IL250391B (enExample)
MX (1) MX2017001620A (enExample)
SG (1) SG11201700816YA (enExample)
WO (1) WO2016022969A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME02420B (me) 2006-09-26 2016-09-20 Celgene Corp 5-supstituirani derivati kinazolinona kao sredstva protiv raka
DK2683708T3 (da) 2011-03-11 2018-01-29 Celgene Corp Faste former af 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidin-2,6-dion og farmaceutiske sammensætninger og anvendelser deraf
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
EP2892887B1 (en) 2012-09-04 2020-07-15 Celgene Corporation Isotopologues of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl) piperidine-2-6-dione and methods of preparation thereof
BR112015010955A2 (pt) 2012-11-16 2017-07-11 Calithera Biosciences Inc inibidores de glutaminase heterocíclica
SG11201610333VA (en) 2014-06-13 2017-01-27 Calithera Biosciences Inc Combination therapy with glutaminase inhibitors
MX2017001620A (es) 2014-08-07 2017-05-10 Calithera Biosciences Inc Formas cristalinas de inhibidores de glutaminasa.
BR112017020780A2 (pt) * 2015-03-30 2018-06-26 Calithera Biosciences Inc métodos de administração de inibidores de glutaminase
AU2016246521B2 (en) 2015-04-06 2020-07-09 Calithera Biosciences, Inc. Treatment of lung cancer with inhibitors of glutaminase
EP3359150A4 (en) 2015-10-05 2019-11-06 Calithera Biosciences, Inc. COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS AND IMMUNO-ONCOLOGICAL AGENTS
US10195197B2 (en) 2016-08-25 2019-02-05 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
KR20190040302A (ko) 2016-08-25 2019-04-17 칼리테라 바이오사이언시즈, 인코포레이티드 글루타미나제 억제제와의 병용 요법
US20210177880A1 (en) * 2017-10-31 2021-06-17 President And Fellows Of Harvard College Methods and compositions for treating acute myeloid leukemia
US20220153780A1 (en) * 2019-03-26 2022-05-19 Tonix Pharma Holdings Limited Salt forms of s-(n, n-diethylcarbamoyl)glutathione
CN114295836B (zh) * 2021-12-22 2024-12-31 融智生物科技（青岛）有限公司 一种计算设备、存储介质和胶质瘤idh分型检测装置及系统

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1019519A (en) 1911-07-11 1912-03-05 Oscar Martin Polin Apparatus for making backing for teeth.
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
DE69839355T2 (de) 1997-07-29 2009-06-04 Alcon Laboratories, Inc., Fort Worth Ophthalmische Zusammensetzungen enthaltend Galaktomannanpolymere und Borat
US5955476A (en) 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
AU2483599A (en) 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
US6451828B1 (en) 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
AU2002305926A1 (en) 2001-02-05 2002-10-08 Exegenics Inc. Cysteine protease inhibitors
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
EP1654002B2 (en) 2003-08-07 2014-01-29 Allergan, Inc. Compositions for delivery of therapeutics into the eyes
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
ES2367311T3 (es) 2004-04-15 2011-11-02 University Of Florida Research Foundation, Inc. Productos de degradación proteolítica de map-2 como biomarcadores de diagnóstico para las lesiones neurales.
CL2007002670A1 (es) 2006-09-15 2008-05-16 Celgene Corp Soc Organizada Ba Compuestos derivados de n-metilaminometil-isoindolina; composicion farmaceutica; forma de dosificacion, util para tratar o prevenir enfermedades tales como cancer, dolor, trastorno pulmonar, trastorno del snc y aterosclerosis.
TW200911798A (en) 2007-08-02 2009-03-16 Amgen Inc PI3 kinase modulators and methods of use
KR101325374B1 (ko) 2008-02-19 2013-11-08 가부시키가이샤 오츠까 세이야꾸 고죠 신체 기능의 회복에 유용한 경구 또는 경장 조성물
US8716314B2 (en) 2009-02-11 2014-05-06 Celgene Corporation Isotopologues of thalidomide
US20120053159A1 (en) 2009-02-11 2012-03-01 Muller George W Isotopologues of lenalidomide
PL3202460T3 (pl) 2010-02-11 2019-12-31 Celgene Corporation Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania
WO2011143160A2 (en) 2010-05-10 2011-11-17 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
US10064885B2 (en) 2010-07-09 2018-09-04 Massachusetts Institute Of Technology Metabolic gene, enzyme, and flux targets for cancer therapy
WO2012068512A1 (en) 2010-11-18 2012-05-24 Deuteria Pharmaceuticals Llc 3-deutero-pomalidomide
WO2012097116A2 (en) 2011-01-14 2012-07-19 Celgene Corporation Isotopologues of isoindole derivatives
CA2742342A1 (en) 2011-02-12 2012-08-12 Baylor Research Institute Msh3 expression status determines the responsiveness of cancer cells to the chemotherapeutic treatment with parp inhibitors and platinum drugs
FI20115876A0 (fi) 2011-09-06 2011-09-06 Turun Yliopisto Yhdistelmähoito
JP5712882B2 (ja) * 2011-09-28 2015-05-07 株式会社豊田自動織機 電動圧縮機用の電動モータ
CN103030597B (zh) 2011-09-30 2014-10-01 南昌滨西科技有限公司 肾脏型谷氨酰胺酶抑制剂及其制备方法和用途
US8604016B2 (en) * 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
HRP20192144T1 (hr) * 2011-11-21 2020-02-21 Calithera Biosciences Inc. Heterociklični inhibitori glutaminaze
EP2855698A4 (en) 2012-05-24 2016-03-30 Dana Farber Cancer Inst Inc OBTAINING TO THE GLUTAMINE-TO-PYRUVAT SIGNAL PATH FOR THE TREATMENT OF CANCER ASSOCIATED WITH THE KRAS ONKOGEN
EP2892537A1 (en) 2012-09-10 2015-07-15 Celgene Corporation Methods for the treatment of locally advanced breast cancer
EP2895623B1 (en) 2012-09-17 2018-08-22 Agios Pharmaceuticals, Inc. Use of e-cadherin and vimentin for selection of treatment responsive patients
BR112015010955A2 (pt) * 2012-11-16 2017-07-11 Calithera Biosciences Inc inibidores de glutaminase heterocíclica
MX369691B (es) 2012-11-21 2019-11-19 Agios Pharmaceuticals Inc Inhibidores de glutaminasa y métodos de empleo.
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
CA2892817A1 (en) * 2012-12-03 2014-06-12 Calithera Biosciences Inc. Treatment of cancer with heterocyclic inhibitors of glutaminase
WO2015061432A1 (en) 2013-10-25 2015-04-30 Calithera Biosciences, Inc. Treatment of viral infections with inhibitors of glutaminase
US20150258082A1 (en) 2014-03-14 2015-09-17 Francesco Parlati Combination therapy with glutaminase inhibitors
US10221459B2 (en) 2014-05-13 2019-03-05 Case Western Reserve University Compositions and methods of treating cancer harboring PIKC3A mutations
SG11201610333VA (en) 2014-06-13 2017-01-27 Calithera Biosciences Inc Combination therapy with glutaminase inhibitors
WO2016004418A1 (en) 2014-07-03 2016-01-07 Board Of Regents, University Of Texas System Glutaminase inhibitor therapy
WO2016014890A1 (en) 2014-07-24 2016-01-28 Calithera Biosciences, Inc. Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase
MX2017001620A (es) 2014-08-07 2017-05-10 Calithera Biosciences Inc Formas cristalinas de inhibidores de glutaminasa.
WO2016054388A1 (en) 2014-10-03 2016-04-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Glutaminase inhibitors
WO2016077632A2 (en) 2014-11-13 2016-05-19 Buck Institute For Research On Aging Inhibition of proline catabolism for the treatment of cancer and other therapeutic applications
BR112017020780A2 (pt) 2015-03-30 2018-06-26 Calithera Biosciences Inc métodos de administração de inibidores de glutaminase
AU2016246521B2 (en) 2015-04-06 2020-07-09 Calithera Biosciences, Inc. Treatment of lung cancer with inhibitors of glutaminase
EP3359150A4 (en) 2015-10-05 2019-11-06 Calithera Biosciences, Inc. COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS AND IMMUNO-ONCOLOGICAL AGENTS
US10195197B2 (en) 2016-08-25 2019-02-05 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
WO2018039442A1 (en) 2016-08-25 2018-03-01 Calithera Biosciences, Inc. Treatment of cancer with inhibitors of glutaminase
KR20190040302A (ko) 2016-08-25 2019-04-17 칼리테라 바이오사이언시즈, 인코포레이티드 글루타미나제 억제제와의 병용 요법
US20200038398A1 (en) 2017-03-10 2020-02-06 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors

Also Published As

Publication number Publication date
EP3193876B1 (en) 2022-01-12
CN106999490A (zh) 2017-08-01
AU2019284149A1 (en) 2020-01-30
KR20170082494A (ko) 2017-07-14
EA037738B1 (ru) 2021-05-17
CA2957225A1 (en) 2016-02-11
US20190359607A1 (en) 2019-11-28
AU2015300825A1 (en) 2017-03-09
WO2016022969A1 (en) 2016-02-11
JP2020037588A (ja) 2020-03-12
EA201790337A1 (ru) 2017-09-29
IL250391A0 (en) 2017-03-30
BR112017002403A2 (pt) 2017-12-05
JP2017523991A (ja) 2017-08-24
EP3193876A4 (en) 2017-12-27
US10316030B2 (en) 2019-06-11
JP2021165286A (ja) 2021-10-14
EP3193876A1 (en) 2017-07-26
US20170226101A1 (en) 2017-08-10
US10676472B2 (en) 2020-06-09
IL250391B (en) 2021-10-31
MX2017001620A (es) 2017-05-10
AU2015300825B2 (en) 2019-10-10
SG11201700816YA (en) 2017-02-27

Similar Documents

Publication Publication Date Title
JP6889101B2 (ja) グルタミナーゼ阻害剤の結晶形態
JP7476380B2 (ja) 血液学的障害を治療するための化合物および組成物
JP6275153B2 (ja) ヘテロ環式グルタミナーゼ阻害剤
EP3600270B1 (en) Compounds and compositions for treating hematological disorders
JP6798890B2 (ja) グルタミナーゼ阻害剤との併用療法
JP2021185146A (ja) アルギナーゼ活性を阻害するための組成物および方法
JP2020510032A (ja) グルタミナーゼ阻害剤との併用療法
KR20170132333A (ko) 글루타미나제 억제제에 의한 폐암의 치료
CN116710776A (zh) 治疗疾病和病症的方法
CN106589055A (zh) 取代的细胞酰二肽类化合物及其制备方法和用途
CN117120054A (zh) 治疗癌症的组合疗法
JP2020536872A (ja) ３−置換１，２，４−オキサジアゾールの結晶形態
CN119156458A (zh) 用irak4修饰化合物治疗疾病和病症
WO2021046178A1 (en) Compounds and methods for treating cancer
US20250042918A1 (en) Compounds
HK40104383A (zh) 用於治疗血液病的化合物和组合物
HK40096682A (zh) 治疗疾病和病症的方法
HK40101281A (zh) 治疗癌症的组合疗法
WO2024077223A1 (en) Protein phosphatase 2a activators
JP2025533522A (ja) 脳腫瘍、乳癌、膵臓癌、及び肺癌の治療に使用されるバノキセリン
HK1241722A1 (en) Crystal forms of glutaminase inhibitors
HK40031549B (zh) 用於治疗血液病的化合物和组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180713

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180713

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190314

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190614

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190718

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191118

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20191118

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20191126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20191128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20191225

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200123

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20200124

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20200207

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20200212

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200818

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20201207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210308

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210413

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20210415

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20210513

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20210513

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210520

R150 Certificate of patent or registration of utility model

Ref document number: 6889101

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees